A phase 2b trial using seven dosing regimens of a novel neurokinin-3 receptor antagonist, fezolinetant, shows statistically significant improvement in vasomotor symptoms vs. placebo in postmenopausal women.
Epilepsy affects about 50 million people worldwide and is responsible for up to 0.5% of the global burden of disease. Although many people learn to handle their epilepsy at home, patients often are brought to the emergency department if they have a seizure in public or it is their first seizure.
In this group of patients hospitalized with severe COVID-19, the majority of whom required invasive ventilation, 68% showed clinical improvement after treatment with remdesivir on a compassionate-use basis.
In this randomized, double-blind, controlled trial, routine treatment with metronidazole compared to placebo in addition to doxycycline and ceftriaxone reduced the presence of endometrial anaerobes, Mycoplasma genitalium, and pelvic tenderness at 30 days post-treatment. However, clinical improvement at three days post-treatment was no different between the two groups.
This article will evaluate and assess medical marijuana, also called medical cannabis, and will cover benefits and risks, clinical considerations affecting its recommendation, and currently available evidence.